

# Tateaki Naito

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9118982/tateaki-naito-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197  
papers

4,561  
citations

32  
h-index

61  
g-index

231  
ext. papers

5,314  
ext. citations

3.4  
avg, IF

5.03  
L-index

#	Paper	IF	Citations
197	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.. <i>Cancer</i> , <b>2022</b> ,	6.4	2
196	Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review. <i>Asia-Pacific Journal of Oncology Nursing</i> , <b>2021</b> , 8, 498-507	2.2	
195	Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , <b>2021</b> , 21, 1247	4.8	0
194	Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer.. <i>Lung Cancer</i> , <b>2021</b> , 164, 39-45	5.9	0
193	Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , <b>2021</b> , 1	4.3	0
192	Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors. <i>Japanese Journal of Clinical Oncology</i> , <b>2021</b> , 51, 1736-1743	2.8	0
191	Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis. <i>Investigational New Drugs</i> , <b>2021</b> , 1	4.3	1
190	Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities. <i>Radiation Oncology</i> , <b>2021</b> , 16, 52	4.2	4
189	Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e21113-e21113 <sup>2,2</sup>		
188	Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1716-1723	4.3	3
187	Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer. <i>Journal of Multidisciplinary Healthcare</i> , <b>2021</b> , 14, 1521-1532	2.8	0
186	Development of home-based resistance training for older patients with advanced cancer: The exercise component of the nutrition and exercise treatment for advanced cancer program. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 952-955	3.6	4
185	Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1732-1741	4.3	0
184	Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression. <i>Lung Cancer</i> , <b>2021</b> , 151, 60-68	5.9	8
183	Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy. <i>Cancer Science</i> , <b>2021</b> , 112, 359-368	6.9	3
182	Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. <i>Cancer Medicine</i> , <b>2021</b> , 10, 247-256	4.8	8
181	Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 571-577	4.3	4

180	Days Spent at Home near the End of Life in Japanese Elderly Patients with Lung Cancer: Analysis of A Prospective Study. <i>Asia-Pacific Journal of Oncology Nursing</i> , <b>2021</b> , 8, 228-236	2.2	
179	Clinical impact of walking capacity on the risk of disability and hospitalizations among elderly patients with advanced lung cancer. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 3961-3970	3.9	1
178	Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 1	4.9	1
177	Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation. <i>Cancer Medicine</i> , <b>2021</b> , 10, 7503-7513	4.8	1
176	Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. <i>Supportive Care in Cancer</i> , <b>2021</b> , 1	3.9	1
175	Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 659-669	4.2	1
174	Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review. <i>Asia-Pacific Journal of Oncology Nursing</i> , <b>2021</b> , 8, 498-507	2.2	2
173	PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2020</b> , 50, 617-622	2.8	8
172	Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1612-1617	4.3	4
171	Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e405-e414	4.9	11
170	Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 605-614	3.5	0
169	Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors. <i>Japanese Journal of Clinical Oncology</i> , <b>2020</b> , 50, 859-866	2.8	11
168	Development of the Early Nutritional Intervention for Elderly Patients with Advanced Cancer: Details of Nutritional Intervention in the Multimodal NEXTAC-ONE Program. <i>Palliative Care Research</i> , <b>2020</b> , 15, 71-80	0.1	
167	Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease. <i>Respirology</i> , <b>2020</b> , 25, 850-854	3.6	5
166	Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 194-201	4.3	2
165	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , <b>2020</b> , 1, 100020	1.4	5
164	Management of anorexia prevents skeletal muscle wasting during cisplatin-based chemotherapy for thoracic malignancies. <i>JCSM Clinical Reports</i> , <b>2020</b> , 5, 8-15	1.5	2
163	Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia. <i>Asia-Pacific Journal of Oncology Nursing</i> , <b>2019</b> , 6, 227-233	2.2	14

162	Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status. <i>Nutrition and Cancer</i> , <b>2019</b> , 71, 767-771	2.8	5
161	A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. <i>BMC Cancer</i> , <b>2019</b> , 19, 528	4.8	22
160	Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. <i>Anticancer Research</i> , <b>2019</b> , 39, 1463-1468	2.3	3
159	Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 604-613	4	23
158	Foreign Body Impaction in the Esophagus. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 923	6.4	
157	Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 184-187	4.3	2
156	Acquired immunodeficiency associated with thymoma: a case report. <i>BMC Cancer</i> , <b>2019</b> , 19, 762	4.8	3
155	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. <i>Cancer</i> , <b>2019</b> , 125, 4294-4302	6.4	42
154	Efficacy of daikenchuto, a traditional Japanese Kampo medicine, for postoperative intestinal dysfunction in patients with gastrointestinal cancers: meta-analysis. <i>International Journal of Clinical Oncology</i> , <b>2019</b> , 24, 1385-1396	4.2	5
153	Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer. <i>In Vivo</i> , <b>2019</b> , 33, 2229-2234	2.3	4
152	Changes in TROP2 expression in lung cancer patients receiving anticancer treatments.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e14732-e14732	2.2	1
151	The impact of steroid use on efficacy of immunotherapy among patients with lung cancer who have developed immune-related adverse events.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e20583-e20583	2.2	1
150	Impact of baseline number of metastases on the efficacy of PD-1 inhibitor monotherapy for non-small cell lung cancer with high PD-L1 expression.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e20551-e20551	2.2	1
149	Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review. <i>Therapeutics and Clinical Risk Management</i> , <b>2019</b> , 15, 1253-1266	2.9	17
148	Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , <b>2019</b> , 128, 152-157	5.9	9
147	Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210074	3.7	10
146	Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2019</b> , 10, 73-83	10.3	57
145	CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. <i>Tumor Biology</i> , <b>2018</b> , 40, 1010428318760420	2.9	12

144	Characteristics of cellular composition in malignant pericardial effusion and its association with the clinical course of carcinomatous pericarditis. <i>Japanese Journal of Clinical Oncology</i> , <b>2018</b> , 48, 291-294	2.8	5
143	Crizotinib-induced simultaneous multiple cardiac toxicities. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 949-951	4.3	2
142	ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease. <i>Lung Cancer</i> , <b>2018</b> , 121, 48-53	5.9	12
141	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. <i>Cancer Science</i> , <b>2018</b> , 109, 2539-2548	6.9	24
140	Efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2018</b> , 48, 822-826	2.8	1
139	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. <i>International Journal of Clinical Oncology</i> , <b>2018</b> , 23, 1052-1059	4.2	20
138	Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1571-1579	8.7	2
137	Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy. <i>Oncotarget</i> , <b>2018</b> , 9, 17664-17674	3.3	18
136	A randomized phase II study of the nutritional and exercise treatment for the elderly patients with advanced non-small cell lung or pancreatic cancer: The NEXTAC-TWO study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS10131-TPS10131	2.2	
135	Optimal treatment sequence for untreated EGFR-mutant NSCLC with brain metastases.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14021-e14021	2.2	
134	Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). <i>Cancer</i> , <b>2018</b> , 124, 606-616	6.4	75
133	Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e247-e252	4.9	28
132	Impact of Cancer Cachexia on Hospitalization-associated Physical Inactivity in Elderly Patients with Advanced Non-small-cell Lung Cancer. <i>Asia-Pacific Journal of Oncology Nursing</i> , <b>2018</b> , 5, 377-382	2.2	14
131	Promotion of Behavioral Change and the Impact on Quality of Life in Elderly Patients with Advanced Cancer: A Physical Activity Intervention of the Multimodal Nutrition and Exercise Treatment for Advanced Cancer Program. <i>Asia-Pacific Journal of Oncology Nursing</i> , <b>2018</b> , 5, 383-390	2.2	24
130	A Patient with a Massive Single Cardiac Metastasis of Lung Adenocarcinoma, Diagnosed via a Biopsy. <i>Internal Medicine</i> , <b>2018</b> , 57, 1637-1640	1.1	
129	Gefitinib-Induced Cardiomyopathy in Epidermal Growth Receptor-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, e207-e208	8.9	6
128	Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy. <i>Journal of Cancer</i> , <b>2018</b> , 9, 2054-2060	4.5	14
127	Development of Low-intensity Home-based Resistance Training for Elderly Patients with Advanced Cancer: The Exercise Component of the NEXTAC Program. <i>Palliative Care Research</i> , <b>2018</b> , 13, 373-381	0.1	

126	Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 519-526.e1	4.9	3
125	Skeletal muscle loss and prognosis of breast cancer patients. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 2221-2227	3.7	17
124	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , <b>2017</b> , 22, 690-697	4.2	17
123	The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 1229-1237	3.5	11
122	A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. <i>Japanese Journal of Clinical Oncology</i> , <b>2017</b> , 47, 840-843	2.8	12
121	Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer. <i>Respirology</i> , <b>2017</b> , 22, 1379-1385	3.6	15
120	Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma. <i>Molecular and Clinical Oncology</i> , <b>2017</b> , 6, 718-722	1.6	8
119	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 719-723	4.9	10
118	Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2017</b> , 106, 138-144	5.9	14
117	High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy. <i>Annals of Oncology</i> , <b>2017</b> , 28, 669-670	10.3	31
116	ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. <i>BMC Cancer</i> , <b>2017</b> , 17, 471	4.8	16
115	Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. <i>BMC Cancer</i> , <b>2017</b> , 17, 800	4.8	34
114	Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 3741-3747	3.7	27
113	Tracheal granuloma 7 years after extubation. <i>Respirology Case Reports</i> , <b>2017</b> , 5, e00252	0.9	1
112	Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 609-614	3.5	8
111	Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 135, 299-306	4.8	2
110	Cardiac Dysfunction Caused by Osimertinib. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, e159-e160	8.9	11
109	The effects of advanced age and serum β <sub>2</sub> -microglobulin on docetaxel unbound exposure and dose-limiting toxicity in cancer patients. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 2416-2425	3.8	10



108	Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. <i>BMC Cancer</i> , <b>2017</b> , 17, 571	4.8	39
107	Long-term clinical outcomes of ALK inhibitors in patients with ALK-positive advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20542-e20542	2.2	
106	Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity. <i>Lung Cancer</i> , <b>2016</b> , 99, 151-4	5.9	17
105	Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. <i>BMC Cancer</i> , <b>2016</b> , 16, 864	4.8	31
104	Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 432-3	8.9	28
103	Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy. <i>Molecular and Clinical Oncology</i> , <b>2016</b> , 5, 575-578	1.6	6
102	Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer. <i>Cancer Science</i> , <b>2016</b> , 107, 1018-21	6.9	11
101	Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure. <i>Cancer Science</i> , <b>2016</b> , 107, 1001-5	6.9	66
100	The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. <i>International Journal of Clinical Oncology</i> , <b>2015</b> , 20, 668-73	4.2	10
99	Primary malignant melanoma of the trachea: A case report. <i>Oncology Letters</i> , <b>2015</b> , 9, 657-660	2.6	5
98	Disease flare after gefitinib discontinuation. <i>Respiratory Investigation</i> , <b>2015</b> , 53, 68-72	3.4	7
97	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 521-6	3.5	48
96	The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 755-60	4.3	5
95	Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. <i>SpringerPlus</i> , <b>2015</b> , 4, 152		5
94	Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2015</b> , 38, 28-32	2.7	14
93	Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. <i>BMC Cancer</i> , <b>2015</b> , 15, 989	4.8	25
92	Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy. <i>Radiology and Oncology</i> , <b>2015</b> , 49, 409-15	3.8	6
91	Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 1699-708	3.9	91

90	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. <i>Annals of Thoracic Medicine</i> , <b>2015</b> , 10, 61-6	2.2	26
89	Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens. <i>International Journal of Clinical Oncology</i> , <b>2014</b> , 19, 63-7	4.2	12
88	Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. <i>BMC Cancer</i> , <b>2014</b> , 14, 18	4.8	24
87	Molecular profiling of small cell lung cancer in a Japanese cohort. <i>Lung Cancer</i> , <b>2014</b> , 84, 139-44	5.9	29
86	Identification of actionable mutations in malignant pleural mesothelioma. <i>Lung Cancer</i> , <b>2014</b> , 86, 35-40	5.9	18
85	Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1948-1953	10.3	28
84	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. <i>Medical Oncology</i> , <b>2014</b> , 31, 88	3.7	13
83	Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. <i>Respiratory Investigation</i> , <b>2014</b> , 52, 101-6	3.4	5
82	Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesions. <i>Respiratory Investigation</i> , <b>2014</b> , 52, 184-9	3.4	7
81	Perianal metastasis of non-small cell lung cancer. <i>Internal Medicine</i> , <b>2014</b> , 53, 1149-52	1.1	5
80	<sup>18</sup> F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms. <i>Oncology Reports</i> , <b>2014</b> , 31, 209-15	3.5	5
79	Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. <i>Neoplasia</i> , <b>2014</b> , 61, 233-40	3.3	22
78	Multiplexed molecular profiling of lung cancer using pleural effusion. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1048-1052	8.9	31
77	Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 86, 339-43	5.9	3
76	Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2014</b> , 5, 121-5	3.2	1
75	The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who received concurrent chemoradiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2014</b> , 37, 144-7	2.7	33
74	Prognostic impact of <sup>18</sup> F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy. <i>Respiratory Investigation</i> , <b>2014</b> , 52, 121-8	3.4	4
73	Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e19032-e19032	2.2	



72	Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. <i>Anticancer Research</i> , <b>2014</b> , 34, 1975-81	2.3	13
71	Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. <i>BMC Cancer</i> , <b>2013</b> , 13, 354	4.8	35
70	The role of $\beta$ -tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. <i>International Journal of Clinical Oncology</i> , <b>2013</b> , 18, 371-9	4.2	24
69	Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1493-8	3.5	3
68	Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 859-65	3.5	7
67	Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e417-9	2.2	16
66	Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 440-5	4.9	12
65	Microcavity array system for size-based enrichment of circulating tumor cells from the blood of patients with small-cell lung cancer. <i>Analytical Chemistry</i> , <b>2013</b> , 85, 5692-8	7.8	80
64	The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1653-9	10.3	26
63	Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older. <i>Japanese Journal of Clinical Oncology</i> , <b>2013</b> , 43, 176-83	2.8	4
62	Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine. <i>Chemotherapy</i> , <b>2013</b> , 59, 307-13	3.2	8
61	Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery. <i>Molecular and Clinical Oncology</i> , <b>2013</b> , 1, 949-952	1.6	5
60	Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. <i>Cancer Science</i> , <b>2013</b> , 104, 1039-44	6.9	8
59	Papillary squamous cell carcinoma of the trachea associated with human papillomavirus-18 infection. <i>Internal Medicine</i> , <b>2013</b> , 52, 2785-8	1.1	1
58	Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. <i>PLoS ONE</i> , <b>2013</b> , 8, e67466	3.7	131
57	Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 7572-7572	2.2	2
56	Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. <i>Anticancer Research</i> , <b>2013</b> , 33, 3279-84	2.3	6
55	Biological correlation of $\beta$ -FDG uptake on PET in pulmonary neuroendocrine tumors. <i>Anticancer Research</i> , <b>2013</b> , 33, 4219-28	2.3	19

54	Prognostic impact of circulating tumor cells in patients with small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 512-9	8.9	135
53	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 2352-63	4.3	52
52	Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI). <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 1777-82	4	4
51	<sup>18</sup> F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study. <i>European Journal of Radiology</i> , <b>2012</b> , 81, 2423-9	4.7	15
50	Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan. <i>Respiratory Investigation</i> , <b>2012</b> , 50, 157-61	3.4	5
49	Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. <i>Lung Cancer</i> , <b>2012</b> , 76, 439-44	5.9	23
48	<sup>18</sup> F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?. <i>Neoplasma</i> , <b>2012</b> , 59, 257-63	3.3	4
47	MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer. <i>Pathology and Oncology Research</i> , <b>2012</b> , 18, 439-47	2.6	9
46	Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 891-9	3.5	71
45	Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer. <i>Anticancer Research</i> , <b>2012</b> , 32, 675-80	2.3	7
44	Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. <i>Anticancer Research</i> , <b>2012</b> , 32, 1103-6	2.3	29
43	Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis. <i>Anticancer Research</i> , <b>2012</b> , 32, 1811-6	2.3	6
42	Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more. <i>Lung Cancer</i> , <b>2011</b> , 71, 173-7	5.9	6
41	Biologic correlates of <sup>18</sup> F-FDG uptake on PET in pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , <b>2011</b> , 71, 144-50	5.9	33
40	Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. <i>Lung Cancer</i> , <b>2011</b> , 74, 419-25	5.9	18
39	Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. <i>Lung Cancer</i> , <b>2011</b> , 74, 457-61	5.9	68
38	The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1242-6	8.9	127
37	Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. <i>Oncology Reports</i> , <b>2011</b> , 26, 931-7	3.5	17

36	Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and $\beta$ -III-tubulin in thymic epithelial tumors. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 606-13	8.9	13
35	Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors. <i>Oncology Letters</i> , <b>2011</b> , 2, 1059-1064	2.6	1
34	Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. <i>Cancer Science</i> , <b>2011</b> , 102, 1032-7	6.9	99
33	Thenar muscle metastasis as recurrence of pulmonary squamous cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2011</b> , 7, 15-6	1.9	3
32	<sup>18</sup> F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. <i>Annals of Nuclear Medicine</i> , <b>2011</b> , 25, 247-53	2.5	23
31	LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , <b>2011</b> , 3, 468-78	3	49
30	Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence. <i>Anticancer Research</i> , <b>2011</b> , 31, 3775-82	2.3	15
29	L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. <i>Anticancer Research</i> , <b>2011</b> , 31, 4075-82	2.3	30
28	Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. <i>Anticancer Research</i> , <b>2011</b> , 31, 4519-23	2.3	19
27	Biologic correlation of 2-[ <sup>18</sup> F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3746-53	2.2	123
26	Long-term survivors of more than 5 years in advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2010</b> , 67, 120-3	5.9	33
25	Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. <i>Lung Cancer</i> , <b>2010</b> , 67, 194-7	5.9	65
24	Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. <i>Lung Cancer</i> , <b>2010</b> , 68, 438-45	5.9	45
23	Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. <i>Lung Cancer</i> , <b>2010</b> , 68, 99-104	5.9	46
22	Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 460-5	8.9	95
21	Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , <b>2010</b> , 15, 161-5	4.2	13
20	N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. <i>International Journal of Clinical Oncology</i> , <b>2010</b> , 15, 484-8	4.2	12
19	Intestinal metastasis from non-small-cell lung cancer initially detected by <sup>18</sup> F-fluorodeoxyglucose positron emission tomography. <i>Japanese Journal of Radiology</i> , <b>2010</b> , 28, 684-7	2.9	12

18	Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , <b>2010</b> , 24, 697-705	2.5	12
17	CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. <i>Oncology Reports</i> , <b>2010</b> , 24, 861-7	3.5	12
16	Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. <i>Radiology</i> , <b>2009</b> , 252, 247-54	20.5	124
15	Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6. <i>International Journal of Clinical Oncology</i> , <b>2009</b> , 14, 534-6	4.2	4
14	Cumulative incidence of and predictive factors for lung cancer in IPF. <i>Respirology</i> , <b>2009</b> , 14, 723-8	3.6	189
13	Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 846-53	4.6	164
12	Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study. <i>Japanese Journal of Clinical Oncology</i> , <b>2009</b> , 39, 158-62	2.8	11
11	Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib. <i>Anticancer Research</i> , <b>2009</b> , 29, 2747-51	2.3	14
10	Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. <i>Respirology</i> , <b>2008</b> , 13, 452-60	3.6	555
9	Lung dendritic cells have a potent capability to induce production of immunoglobulin A. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2008</b> , 38, 161-7	5.7	23
8	S-1 treatment for chemorefractory thymic carcinoma. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 1076	8.9	10
7	Reactive Legionella pneumophila arthritis diagnosed by polymerase chain reaction. <i>Rheumatology International</i> , <b>2007</b> , 27, 415-6	3.6	6
6	Interstitial lung diseases associated with amyopathic dermatomyositis. <i>European Respiratory Journal</i> , <b>2006</b> , 28, 1005-12	13.6	109
5	A validation and potential modification of the pneumonia severity index in elderly patients with community-acquired pneumonia. <i>Journal of the American Geriatrics Society</i> , <b>2006</b> , 54, 1212-9	5.6	31
4	Lymphangitis carcinomatosa as a potential predictor for a response to gefitinib. <i>Clinical Oncology</i> , <b>2006</b> , 18, 573-4	2.8	0
3	Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 171, 707-13	10.2	66
2	Efficacy of a consensus protocol therapy in adults with acute, severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2003</b> , 90, 331-7	3.2	4
1	Well-differentiated hepatocellular carcinoma showing intrahepatic neural invasion: autopsied case. <i>Japanese Journal of Clinical Oncology</i> , <b>1991</b> , 21, 143-6	2.8	2

